CPhI Russia returns for 5th edition

CPhI Russia is returning this year for its 5th edition; coinciding with the government’s Pharma 2020 plan to help stimulate demand for international pharmaceutical ingredients, manufacturing and packaging equipment.

The three-day trade show will see over 3000 attendees form 664 countries alongside 199 exhibitors network and do business.

Attendees will be able to gain insights from the International Forum, a dedicated matchmaking programme, speaker sessions and other networking opportunities. The programme includes detailed analysis on ‘Compulsory licensing: features, opportunities and threats’, ‘Drugs labelling: first experience and prospects’, ‘Modern assortment solutions and global trends in the pharmaceutical packaging industry’. As well as a session that explores the dramatic rise in new machinery and the move towards increased GM standards – entitled ‘Russian inspectorate does not sleep. Latest news about GMP’.

The event will also include the P-MEC zone, intended for pharma machinery specialists, and the Innopack zone, intended for pharma packaging professionals.

Partnerships and deals struck at CPhI Russia in the past have helped emerging pharma markets. By 2019 the Russian pharma market is expected to reach $31.2 billion. A government commitment to invest nearly $5 billion in funding to bring existing manufacturing sites to GMP standards, is driving increased interest in the event. Under the new plan, foreign investment is also encouraged through a fast-track approval process and tax incentives.

Orhan Caglayan, brand director at CPhI Russia said: “We are seeing a steady growth in three main areas driven by a gentrifying healthcare sector, a rising local population and government support for domestic manufacturing. Currency variation aside, the pharma market is growing at just under 10% year-on-year and distributers, APIs manufacturers and machinery providers are seeing high demand across Russia and CIS countries. Traditionally, Russia has been a hard market to enter and that is why CPhI Russia has become so intertwined with the market’s growth.

"The Russia pharma market has yet to reach its full potential and by bringing together regional companies with C-level executives, we hope to speed its development. The unique content and market analysis at the event are essential in helping both domestic and international companies evaluate best opportunities for partnerships and growth”.